An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development.

EGFR bi-armed autologous activated T cells - Barbara Ann Karmanos Cancer Institute

Krazati (adagrasib) - BMS

Lumakras (sotorasib) - Amgen

MRTX1133 - BMS

http://www.ncbi.nlm.nih.gov/pubmed/41503677

Asfar Azmi; Muhammad Wasif Saif; Shadi Chamseddine

Jan 8, 2026